1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Pak Fah Yeow International Limited

Pak Fah Yeow International Limited

0239.HK
Pak Fah Yeow International LimitedHK flagHong Kong Stock Exchange
2.33
HKD
-0.08
- -
726.12MMarket Cap
Pak Fah Yeow International Limited
0239.HK
(Hong Kong Stock Exchange)

Recent

price

2.33

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.35
0.37
0.41
0.52
0.6
0.58
0.59
0.57
0.45
0.48
0.35
0.45
0.47
0.83
0.76
- -
Revenue per Share
0.18
0.15
0.21
0.23
0.47
0.2
0.2
0.33
0.12
0.12
-0.12
0.12
0.1
0.34
0.25
- -
Basic EPS, GAAP
0.11
0.05
0.22
0.17
0.13
0.23
0.21
0.31
0.17
0.16
0.02
0.22
0.13
0.46
0.25
- -
Free Cash Flow per Basic Share
0.13
0.13
0.11
0.14
0.16
0.18
0.12
0.13
0.14
0.11
0.08
0.07
0.08
0.15
0.21
- -
Dividend per Share
0.77
0.79
0.82
0.89
1.18
1.26
1.33
1.53
1.56
1.59
1.41
1.47
1.49
1.63
1.7
- -
Book Value per Share
1.15
1.24
1.52
1.65
1.99
2
2.02
2.39
2.42
2.43
2.15
2.26
2.26
2.45
2.34
- -
Tangible Book Value per Share
312
312
312
312
312
312
312
312
312
312
312
312
312
312
312
- -
Basic Weighted Avg Shares
108
116
129
161
186
182
183
179
142
148
110
140
147
259
237
214
Sales/Revenue/Turnover
33.66
25.51
31.59
35.36
38.87
43.38
42.52
40.72
24.91
30.38
28.19
32.64
33.04
55.22
52.97
51.25
Operating Margin (%)
2
2
2
2
2
2
2
2
8
8
8
7
7
7
7
6
Depreciation Expense
55
46
64
71
146
61
61
103
37
36
-38
38
30
105
79
91
Net Income, GAAP
8.89
9.5
9.71
11.11
7.5
17.18
17.19
9.14
14.74
18.56
- -
18.62
20.69
18.45
19.57
15.05
Effective Tax Rate (%)
50.99
39.88
50.06
44.03
78.6
33.55
33.51
57.35
26.33
24.34
-35.03
27.24
20.33
40.51
33.19
42.68
Profit Margin (%)
15
-4
18
13
47
69
95
126
118
132
147
175
194
273
318
367
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
359
388
477
517
623
624
634
749
757
760
673
708
707
765
732
723
Total Equity
7.9
5.99
7.35
9.14
10.79
9.81
9.72
9.21
3.87
4.69
- -
5.25
5.36
15.57
13.25
12.7
Return on Invested Capital (%)
17.92
14.94
20.73
22.52
39.94
14.73
14.23
21.85
7.51
7.17
- -
8.29
6.47
21.48
15.1
16.63
Return on Capital (%)
23.95
18.93
25.66
26.68
45.44
16.06
15.17
23.02
7.74
7.35
-8.2
8.51
6.51
21.6
15.14
16.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.74%
1.53%
-1.25%
Free Cash Flow
93.21%
206.3%
43.98%
Net Income, GAAP
-18.49%
4.11%
16.17%
Sales/Revenue/Turnover
4.68%
18.16%
-9.67%
Total Cash Common Dividend
5.58%
23.51%
-13.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
259
2024
- -
- -
- -
- -
237
2025
- -
- -
- -
- -
214

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.34
2024
- -
- -
- -
- -
0.25
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.15
2024
- -
- -
- -
- -
0.21
2025
- -
- -
- -
- -
- -
Similar Companies
Western Sierra Resource Corporation (WSRC)
PT Tempo Scan Pacific Tbk (TSPC.JK)
Coenzyme-A Inc. (PPII)
Samjin Pharmaceuticals Co., Ltd. (005500.KS)
HLK Biotech Holding Group, Inc. (AMHD)
Evoke Pharma, Inc. (EVOK)
Business
Pak Fah Yeow International Limited (0239.HK) is an investment holding company principally engaged in the manufacture, marketing, and distribution of healthcare products under the Hoe Hin brand; property investments; and treasury investments including equity and debt securities, mutual funds, and dual currency investments. The company offers a diverse portfolio of medicated oils, balms, and ointments such as Hoe Hin White Flower Embrocation (also known as Hoe Hin Pak Fah Yeow), Hoe Hin Strain Relief, Hoe Hin White Flower Ointment, and Fúzai 239 (floral-scented White Flower Embrocation); these products provide relief from headaches, muscular pain, colds, insect bites, and strains, with manufacturing certified under PIC/S GMP, ISO 9001:2015, Therapeutic Goods Administration Australia, and Chinese Medicine Council of Hong Kong standards. It operates healthcare sales in Hong Kong, Macau, the People's Republic of China (including e-commerce expansion), Southeast Asia (notably Philippines and Singapore growth), North America (USA facing potential 2025 tariff risks), the United Kingdom, and internationally; property investments encompass commercial office, industrial, residential, and car park assets in Hong Kong, Singapore, and the United Kingdom; treasury activities focus on fixed deposits and surplus cash optimization. Founded in 1927 and headquartered at 11th Floor, 200 Gloucester Road, Wan Chai, Hong Kong (registered office in Bermuda), the company reported 2024 revenue of HK$236.8 million (down 8.6% year-on-year, with healthcare at 91.8%), underlying recurring profit of HK$103.6 million (down 13.0%), and proposed total dividends of HK20.0 cents per share amid softer China demand post-pandemic, Hong Kong rental pressures, and treasury gains from higher interest; it enhanced digital marketing, online channels in China, and production capacity supporting North America growth while maintaining full occupancy in UK/Singapore properties. No major acquisitions, partnerships, funding rounds, or new product launches occurred in 2024-2025; strategic focus remains on healthcare market expansion, e-commerce acceleration, and prudent asset management.